SCHEMBL5206301

SCHEMBL5206301

CCOC(=O)C(C)Oc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.60
LMNA P02545 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
POLB P06746 3/20 0.54
NR5A1 Q13285 1/20 0.49
EPHX2 P34913 4/20 0.47
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
IDH1 O75874 1/20 0.45
SLC5A1 P13866 1/20 0.45
SLC5A2 P31639 1/20 0.45
EPHX1 P07099 1/20 0.44
MAPT P10636 1/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.43
HRH2 P25021 1/20 0.43
HRH1 P35367 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3990976 0.84 IDH1 (0.58) KMT2ALMNAL3MBTL1POLBEPHX2
SCHEMBL16711903 0.83 POLB (0.52) KMT2ALMNAL3MBTL1POLBEPHX2
SCHEMBL2106687 0.82 LMNA (0.60) KMT2ALMNAL3MBTL1POLBNR5A1
SCHEMBL10487619 0.82 LMNA (0.60) KMT2ALMNAL3MBTL1POLBNR5A1
SCHEMBL3369250 0.82 LMNA (0.60) KMT2ALMNAL3MBTL1POLBNR5A1
SCHEMBL14518118 0.82 LMNA (0.64) KMT2ALMNAL3MBTL1POLBNR5A1
SCHEMBL11548487 0.82 L3MBTL1 (0.63) KMT2ALMNAL3MBTL1POLBEPHX2
SCHEMBL18562096 0.82 LMNA (0.63) KMT2ALMNAL3MBTL1POLBEPHX2
SCHEMBL5205374 0.82 LMNA (0.63) KMT2ALMNAL3MBTL1POLBEPHX2
SCHEMBL9857703 0.82 LMNA (0.63) KMT2ALMNAL3MBTL1POLBEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313717-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-10-17 EP disclosed
US-7176224-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2007-02-13 US disclosed
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY 2004-07-15 US disclosed
EP-1313717-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
WO-2002016332-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARD, PPARG KMT2A 2734/4885LMNA 3917/4885L3MBTL1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.